Boston (U.S.) – Rotterdam (NL), 17 February 2015. SkylineDx today announced the appointment of Saad Usmani, MD, FACP, as their acting Chief Medical Officer. Dr. Usmani is currently the Director of Clinical Research (Hematologic Malignancies) and Director of Plasma Cell Disorders at Carolinas HealthCare System’s Levine Cancer Institute in Charlotte, NC.
In his role Dr. Usmani will be a key member of the executive team of the company. He will lead the overall clinical vision for the company and provide clinical direction to the scientific and commercial organizations. He will also provide leadership to the organization, interact with the Scientific Advisory Board of the company, and interface with key oncology thought leaders. He will also consult with the company to develop their clinical trials and reimbursement strategies.
“Dr. Usmani has a stellar reputation in the Multiple Myeloma community and is seen as a world expert,” says SkylineDx CEO Dharminder Chahal, “Dr. Usmani is very experienced with Gene Expression Profiling and we are privileged to have him as a key part of our team as SkylineDx moves towards commercialization of our product offerings”.
“I am delighted to join SkylineDx in this capacity,” says Dr. Usmani. “I am impressed with the clinical data and the results that the MMprofiler delivers. I look forward to helping them shape their future in the clinical market.” Prior to joining Levine Cancer Institute, Dr. Usmani was the Director of Developmental Therapeutics at the University of Arkansas where he led clinical and translational investigations using novel compounds. He has published numerous articles published in peer-reviewed journals and holds leadership positions in several medical associations. About SkylineDx SkylineDx is a Dutch molecular diagnostics company in oncology, currently focusing on two types of hematological cancer: Multiple Myeloma (MM) and Acute Myeloid Leukemia (AML). It develops and commercializes innovative molecular diagnostic tests based on gene expression profiling. These are prognostic tests with a high clinical value that offer physicians the possibility of making better-informed and personalized therapeutic decisions for their patients. Started as a spin-off from the Rotterdam Erasmus Medical Center in 2005, the company is planning market introduction of their MMprofiler in Europe and the USA by 2015. SkylineDx currently employs a highly skilled multidisciplinary staff of around twenty employees and holds offices in Rotterdam (The Netherlands: R&D, operations, commercial EU) and Boston (MA, USA: commercial).
For further information, questions and interviews please contact:
SkylineDx – U.S.A.
101 Federal Street
Suite 1900
Boston MA 02110
USA
Phone: +1 617 342 7098
SkylineDx B.V. – Europe
Rotterdam Science Tower
Marconistraat 16, 18th floor
3029 AK Rotterdam
The Netherlands
Phone: +31 (0)10 7038410
Help employers find you! Check out all the jobs and post your resume.
In his role Dr. Usmani will be a key member of the executive team of the company. He will lead the overall clinical vision for the company and provide clinical direction to the scientific and commercial organizations. He will also provide leadership to the organization, interact with the Scientific Advisory Board of the company, and interface with key oncology thought leaders. He will also consult with the company to develop their clinical trials and reimbursement strategies.
“Dr. Usmani has a stellar reputation in the Multiple Myeloma community and is seen as a world expert,” says SkylineDx CEO Dharminder Chahal, “Dr. Usmani is very experienced with Gene Expression Profiling and we are privileged to have him as a key part of our team as SkylineDx moves towards commercialization of our product offerings”.
“I am delighted to join SkylineDx in this capacity,” says Dr. Usmani. “I am impressed with the clinical data and the results that the MMprofiler delivers. I look forward to helping them shape their future in the clinical market.” Prior to joining Levine Cancer Institute, Dr. Usmani was the Director of Developmental Therapeutics at the University of Arkansas where he led clinical and translational investigations using novel compounds. He has published numerous articles published in peer-reviewed journals and holds leadership positions in several medical associations. About SkylineDx SkylineDx is a Dutch molecular diagnostics company in oncology, currently focusing on two types of hematological cancer: Multiple Myeloma (MM) and Acute Myeloid Leukemia (AML). It develops and commercializes innovative molecular diagnostic tests based on gene expression profiling. These are prognostic tests with a high clinical value that offer physicians the possibility of making better-informed and personalized therapeutic decisions for their patients. Started as a spin-off from the Rotterdam Erasmus Medical Center in 2005, the company is planning market introduction of their MMprofiler in Europe and the USA by 2015. SkylineDx currently employs a highly skilled multidisciplinary staff of around twenty employees and holds offices in Rotterdam (The Netherlands: R&D, operations, commercial EU) and Boston (MA, USA: commercial).
For further information, questions and interviews please contact:
SkylineDx – U.S.A.
101 Federal Street
Suite 1900
Boston MA 02110
USA
Phone: +1 617 342 7098
SkylineDx B.V. – Europe
Rotterdam Science Tower
Marconistraat 16, 18th floor
3029 AK Rotterdam
The Netherlands
Phone: +31 (0)10 7038410
Help employers find you! Check out all the jobs and post your resume.
